[HTML][HTML] Engineering neoantigen vaccines to improve cancer personalized immunotherapy
Z Liu, J Lv, Q Dang, L Liu, S Weng, L Wang… - … journal of biological …, 2022 - ncbi.nlm.nih.gov
Immunotherapy treatments harnessing the immune system herald a new era of personalized
medicine, offering considerable benefits for cancer patients. Over the past years, tumor …
medicine, offering considerable benefits for cancer patients. Over the past years, tumor …
Application of high-throughput imaging mass cytometry hyperion in cancer research
Imaging mass cytometry (IMC) enables the in situ analysis of in-depth-phenotyped cells in
their native microenvironment within the preserved architecture of a single tissue section. To …
their native microenvironment within the preserved architecture of a single tissue section. To …
Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
The long-term survival of patients with advanced urothelial carcinoma (UCa) is limited
because of innate resistance to treatment. We identified elevated expression of the histone …
because of innate resistance to treatment. We identified elevated expression of the histone …
Spatial immunoprofiling of adenoid cystic carcinoma reveals B7-H4 is a therapeutic target for aggressive tumors
LG Sousa, DJ McGrail, F Lazar Neto, K Li… - Clinical Cancer …, 2023 - AACR
Purpose: Adenoid cystic carcinoma (ACC) is a heterogeneous malignancy, and no effective
systemic therapy exists for metastatic disease. We previously described two prognostic ACC …
systemic therapy exists for metastatic disease. We previously described two prognostic ACC …
B7x in cancer immunity and immunotherapy
K Mortezaee - International immunopharmacology, 2023 - Elsevier
B7x (also called B7-H4) is a co-inhibitory molecule of B7 family that is highly expressed in
non-inflamed or cold cancers, and its aberrant expression is contributed to cancer …
non-inflamed or cold cancers, and its aberrant expression is contributed to cancer …
B7 family protein glycosylation: promising novel targets in tumor treatment
L Xiao, X Guan, M Xiang, Q Wang, Q Long… - Frontiers in …, 2022 - frontiersin.org
Cancer immunotherapy, including the inhibition of immune checkpoints, improves the tumor
immune microenvironment and is an effective tool for cancer therapy. More effective and …
immune microenvironment and is an effective tool for cancer therapy. More effective and …
Effects of supplemental chromium nanoparticles on IFN-γ expression of heat stress broilers
O Hamidi, M Chamani, H Ghahri, AA Sadeghi… - Biological trace element …, 2022 - Springer
The aim of present study was to investigate the beneficial effect of chromium (III) picolinate
(CrPic) and chromium (III) picolinate nanoparticles (NCrPic) addition on growth …
(CrPic) and chromium (III) picolinate nanoparticles (NCrPic) addition on growth …
A methylation-based reclassification of bladder cancer based on immune cell genes
Q Luo, TA Vögeli - Cancers, 2020 - mdpi.com
Simple Summary Bladder cancer (BC) development is highly related to immune cell
infiltration. In this study, we aimed to construct a new classification of bladder cancer …
infiltration. In this study, we aimed to construct a new classification of bladder cancer …
Expression of B7–H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas
N Niu, W Shen, Y Zhong, RC Bast Jr, A Jazaeri… - Human pathology, 2021 - Elsevier
High-grade serous ovarian carcinoma (HGSC) is the most lethal gynecologic malignancy.
While immune checkpoint inhibitors against PD-L1 and CTLA-4 have shown significant …
While immune checkpoint inhibitors against PD-L1 and CTLA-4 have shown significant …
[HTML][HTML] Clinical implications of single cell sequencing for bladder cancer
R Yadollahvandmiandoab, M Jalalizadeh… - Oncology …, 2024 - ncbi.nlm.nih.gov
Bladder cancer (BC) is the 10th most common cancer worldwide, with about 0.5 million
reported new cases and about 0.2 million deaths per year. In this scoping review, we …
reported new cases and about 0.2 million deaths per year. In this scoping review, we …